Skip to content
2000
Volume 13, Issue 6
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal. After more than ten years of experience, the safety issues associated with these drugs are well characterized and can be avoided with careful patient selection and tight clinical control. Although the different biologic drugs (anti-TNF agents, anti-IL-6, anti-B cells and anti-costimulation of T-cells) have apparently different mechanisms of action, all biologic agents have demonstrated similar efficacy. In addition results of the combination of two biologic therapies have shown no additive clinical effects, although there is an increased risk of infection. Therefore, further research is needed to optimize the use of these and future targeted therapies in RA.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/15680266113139990093
2013-03-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/15680266113139990093
Loading

  • Article Type:
    Research Article
Keyword(s): adverse effects; biological therapies; clinical response; Rheumatoid arthritis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test